Skip to main content

Table 1 Patient characteristics

From: TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience

Characteristics N (%)/median (IQRa)
Gender
 Male 112(91.1%)
 Female 11(8.9%)
Age 58(47-64)
 < 60 69(56.1%)
 ≥60 54(43.1%)
Aetiology of liver disease
 Hepatitis B 117(95.2%)
 Hepatitis C 3(2.4%)
 Alcoholic cirrhosis 3(2.4%)
BCLC classificationa
 A 14(11.4%)
 B 27(22.0%)
 C 71(57.7%)
 D 11(8.9%)
PVTTa
 No 43(35.0%)
 Yes 80(65.0%)
Number of tumors
 Single 42(34.1%)
 Multiple 81(65.9%)
MELDa 14.50(13.34-15.75)
 <15 76(61.8%)
 ≥15 47(38.2%)
Symptomatic portal hypertension
 Refractory ascites 51(41.5%)
 Variceal bleeding 49(39.8%)
 Both 23(18.7%)
 Refractory diarrhea 5(4.1%)
Laboratory tests
 Platelets [109/L] 88(65-125)
 INRa 1.26(1.15-1.43)
 AST [U/L] a 46.3(34.0-65.0)
 ALT [U/L] a 37.6(25.4-52.1)
 Albumin [g/dL] 33.2(30.2-36.8)
 Creatinine [mg/dL] 72(62.2-86.5)
 Bilirubin [mg/dL] 29.8(19.2-41.0)
 AFP [ng/mL] a 16.2(4.81-463.78)
 <100 42(34.1%)
 ≥100 81(65.9%)
  1. PVTT Portal vein tumor thrombosis, MELD Model of end stage liver disease, INR International normalised ratio, AST Aspartate aminotransferase, ALT Alanine transaminase, AFP Alpha fetoprotein, CI Confidence interval, IQR Interquartile range
  2. aBarcelona Clinic Liver Cancer